TW234125B - - Google Patents

Info

Publication number
TW234125B
TW234125B TW082101800A TW82101800A TW234125B TW 234125 B TW234125 B TW 234125B TW 082101800 A TW082101800 A TW 082101800A TW 82101800 A TW82101800 A TW 82101800A TW 234125 B TW234125 B TW 234125B
Authority
TW
Taiwan
Application number
TW082101800A
Other languages
Chinese (zh)
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929205442A external-priority patent/GB9205442D0/en
Priority claimed from GB929205415A external-priority patent/GB9205415D0/en
Priority claimed from GB929205422A external-priority patent/GB9205422D0/en
Priority claimed from GB929205416A external-priority patent/GB9205416D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of TW234125B publication Critical patent/TW234125B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW082101800A 1992-03-12 1993-03-11 TW234125B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB929205442A GB9205442D0 (en) 1992-03-12 1992-03-12 Novel compounds
GB929205415A GB9205415D0 (en) 1992-03-12 1992-03-12 Novel compounds
GB929205422A GB9205422D0 (en) 1992-03-12 1992-03-12 Novel compounds
GB929205416A GB9205416D0 (en) 1992-03-12 1992-03-12 Novel compounds

Publications (1)

Publication Number Publication Date
TW234125B true TW234125B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1994-11-11

Family

ID=27450844

Family Applications (1)

Application Number Title Priority Date Filing Date
TW082101800A TW234125B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-03-12 1993-03-11

Country Status (6)

Country Link
US (1) US5508288A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0630373A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPH07504429A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9301336A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW234125B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO1993018028A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7918704B2 (en) 2005-08-12 2011-04-05 Au Optronics Corp Organic electroluminescent display panel and method for fabricating same

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014801A1 (en) * 1992-12-29 1994-07-07 Smithkline Beecham Plc Heterocyclic urea derivatives as 5ht2c and 5ht2b antagonists
GB9302275D0 (en) * 1993-02-05 1993-03-24 Smithkline Beecham Plc Novel compounds
GB9306460D0 (en) * 1993-03-29 1993-05-19 Smithkline Beecham Plc Novel compounds
GB9308802D0 (en) * 1993-04-28 1993-06-09 Smithkline Beecham Plc Treatment
GB9420521D0 (en) * 1994-10-12 1994-11-30 Smithkline Beecham Plc Novel compounds
GB9511355D0 (en) * 1995-06-06 1995-08-02 Fujisawa Pharmaceutical Co Urea derivatives
WO1998047868A1 (en) * 1997-04-18 1998-10-29 Smithkline Beecham Plc Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
US6344476B1 (en) 1997-05-23 2002-02-05 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
US6187799B1 (en) * 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9719530D0 (en) * 1997-09-12 1997-11-19 Smithkline Beecham Plc Novel compounds
GB9724372D0 (en) 1997-11-18 1998-01-14 Smithkline Beecham Plc Novel compounds
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
ATE300299T1 (de) * 1997-12-22 2005-08-15 Bayer Pharmaceuticals Corp Inhibierung der raf-kinase durch substituierte heterocyclische harnstoffverbindungen
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
AU2006201959B2 (en) * 1997-12-22 2008-09-04 Bayer Healthcare Llc Inhibition of Raf Kinase using Substituted Heterocyclic Ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
RU2319693C9 (ru) * 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
ES2426938T3 (es) * 2001-12-03 2013-10-25 Bayer Healthcare Llc Compuestos de aril urea en combinación con otros agentes citostáticos o citotóxicos para tratar cánceres humanos
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
SI1580188T1 (sl) * 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
AU2003209116A1 (en) 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
GB0206876D0 (en) * 2002-03-22 2002-05-01 Merck Sharp & Dohme Therapeutic agents
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US8796250B2 (en) * 2003-05-20 2014-08-05 Bayer Healthcare Llc Diaryl ureas for diseases mediated by PDGFR
BRPI0412219B8 (pt) 2003-07-23 2021-07-27 Bayer Healthcare Llc compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos
EP1718616A2 (en) * 2004-02-26 2006-11-08 MERCK PATENT GmbH Isoquinoline derivatives
EP1858879B1 (en) * 2005-01-14 2012-06-06 Gilead Connecticut, Inc. 1,3-diaryl substituted ureas as modulators of kinase activity
WO2007024294A2 (en) * 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
US7470787B2 (en) * 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP2068878B1 (en) 2006-09-20 2019-04-10 Aerie Pharmaceuticals, Inc. Rho kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) * 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
US8450344B2 (en) * 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
ES2834451T3 (es) 2009-05-01 2021-06-17 Aerie Pharmaceuticals Inc Inhibidores de mecanismo doble para el tratamiento de enfermedades
ES2776199T3 (es) 2013-03-15 2020-07-29 Aerie Pharmaceuticals Inc Conjugados de compuestos de isoquinolina y prostaglandinas
CA3005707C (en) 2015-11-17 2023-11-21 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
BR112019020078A2 (pt) 2017-03-31 2020-04-28 Aerie Pharmaceuticals Inc compostos e composições farmacêuticas à base de arilciclopropil-amino-isoquinolinil amida e métodos de uso dos mesmos
US11427563B2 (en) 2018-09-14 2022-08-30 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98927A (pt) * 1990-09-13 1992-07-31 Beecham Group Plc Processo para a preparacao de piridil-indolil-ureias

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7918704B2 (en) 2005-08-12 2011-04-05 Au Optronics Corp Organic electroluminescent display panel and method for fabricating same

Also Published As

Publication number Publication date
JPH07504429A (ja) 1995-05-18
EP0630373A1 (en) 1994-12-28
US5508288A (en) 1996-04-16
WO1993018028A1 (en) 1993-09-16
MX9301336A (es) 1993-10-01

Similar Documents

Publication Publication Date Title
DK0598561T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0553875T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0574087T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0553681T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0571874T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0576097T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK0590732T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE9209779U1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU632452B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU631518B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN180597B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN180664B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BRPI9204323A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2619992A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU640334B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU1849392A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU1933792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2061492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU1809592A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2138992A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2202592A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2527392A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2527592A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP0587365A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU2840792A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)